who shouldn t use glp 1 GLP-1 Drugs: Where We Are and Where We're Going — Summit Re who should not take glp-1

503A compounding pharmacies had until April 2025, and 503B outsourcing facilities until May 2025, to wind down compounded semaglutide production

But more serious rare risks are also possible, including pancreatitis and stomach or gallbladder problems

When initiating both medications, consider staggering the start dates or ensuring one medication is at a stable dose before introducing the other, allowing clearer attribution of any adverse effects

Ernhrung (2016)

FDA-approved GLP-1 medications for weight loss are typically indicated for adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 or higher) who also have at least one weight-related medical condition

Discounts auto-apply